Zerofen 10% Oral Suspension

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

Fenbendazole

Διαθέσιμο από:

Chanelle Pharmaceuticals Manufacturing Limited

Φαρμακολογική κατηγορία (ATC):

QP52AC13

INN (Διεθνής Όνομα):

Fenbendazole

Δοσολογία:

10 percent weight/volume

Φαρμακοτεχνική μορφή:

Oral suspension

Τρόπος διάθεσης:

POM: Prescription Only Medicine as defined in relevant national legislation

Θεραπευτική ομάδα:

Cattle

Θεραπευτική περιοχή:

fenbendazole

Θεραπευτικές ενδείξεις:

Endoparasiticide

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

1991-01-04

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Zerofen 10% Oral Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substances:
Fenbendazole
10
% w/v
Excipients:
Methyl Parahydroxybenzoate
0.2
% w/v
Propyl Parahydroxybenzoate
0.02
% w/v
Amaranth (E123)
0.0015
% w/v
For a full list of excipients, see Section 6.1
3 PHARMACEUTICAL FORM
Oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Zerofen 10% is a broad spectrum anthelmintic for the control of mature
and developing immature forms of the following
major species of roundworm in cattle. In cattle it is effective
against the following parasites:
Gastro-intestinal roundworms:
_Ostertagia_
_Cooperia_
_Trichostrongylus_
_Nematodirus_
_Haemonchus_
_Oesophagostomum_
_Bunostomum_
_Strongyloides_ and
_Trichuris_ species
Lungworms:
_Dictyocaulus viviparus_
It is usually effective against inhibited larvae of Ostertagia species
in cattle.
Zerofen 10% has an ovicidal effect on
nematode eggs.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_7_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_3_
_3_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As with other anthelmintics, veterinary advice should be sought on
appropriate dosing programmes and stock management
to achieve adequate parasite control and reduce the likelihood of
anthelm